文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

入院前糖皮质激素治疗与重症患者30天死亡率的关系:某三级医院混合ICU人群的回顾性研究

Effect of preadmission glucocorticoid therapy on 30-day mortality in critically ill patients: a retrospective study of a mixed ICU population in a tertiary hospital.
PubMed 文献 · Ann Intensive Care · 2019-01-18
一句话结论入ICU前口服糖皮质激素者30天死亡率21.2%,高于未用者的8.8%,校正后HR 1.62(95%CI 1.29-2.03,P<0.001)。

该回顾性队列纳入2012年1月至2017年12月某三级学术医院ICU的24,929例成人患者,其中入院前规律口服糖皮质激素者816例(3.3%),无激素使用史者24,113例。入院前激素使用者30天死亡率21.2%(173/816),非使用者8.8%(2113/24,113)。多因素Cox回归显示入院前激素使用与30天死亡率升高相关(HR 1.62,95%CI 1.29-2.03,P<0.001)。合并糖尿病者HR 2.29(95%CI 1.08-4.86,P=0.031);泼尼松龙日剂量≤5 mg者HR 1.45(95%CI 1.03-2.03,P=0.033),>5 mg者HR 1.67(95%CI 1.25-2.24,P=0.001)。

要点

  • 入院前口服糖皮质激素者30天死亡率21.2%(173/816),非使用者8.8%(2113/24,113)。
  • 多因素Cox回归:入院前激素使用与30天死亡率升高相关(HR 1.62,95%CI 1.29-2.03,P<0.001)。
  • 入院前激素使用者合并糖尿病时30天死亡率升高更明显(HR 2.29,95%CI 1.08-4.86,P=0.031)。
  • 泼尼松龙日剂量≤5 mg者HR 1.45(95%CI 1.03-2.03,P=0.033),>5 mg者HR 1.67(95%CI 1.25-2.24,P=0.001)。
  • 泼尼松龙、甲泼尼龙、地塞米松使用者30天死亡率分别升高(HR 1.56,95%CI 1.21-2.01,P=0.001;HR 1.90,95%CI 1.12-3.25,P=0.018;HR 1.30,95%CI 1.05-1.50,P=0.042)。

适用人群与场景

  • 2012年1月至2017年12月入住某三级学术医院ICU的成人患者,为混合ICU人群。
  • 入院前规律口服糖皮质激素治疗者被归为入院前激素使用者;无激素使用史者归为非激素使用者。

研究设计与关键结果

  • 回顾性队列研究,纳入24,929例成人ICU患者,其中入院前激素使用者816例(3.3%),非使用者24,113例。
  • 主要终点30天死亡率:入院前激素使用者21.2%(173/816)vs 非使用者8.8%(2113/24,113)。
  • 多因素Cox回归:入院前激素使用较非使用者30天死亡率升高(HR 1.62,95%CI 1.29-2.03,P<0.001)。
  • 入院前激素使用者合并糖尿病较非使用者30天死亡率升高(HR 2.29,95%CI 1.08-4.86,P=0.031)。
  • 敏感性分析:泼尼松龙日剂量≤5 mg者较非使用者HR 1.45(95%CI 1.03-2.03,P=0.033),>5 mg者HR 1.67(95%CI 1.25-2.24,P=0.001)。
  • 泼尼松龙使用者较非使用者HR 1.56(95%CI 1.21-2.01,P=0.001),甲泼尼龙使用者HR 1.90(95%CI 1.12-3.25,P=0.018),地塞米松使用者HR 1.30(95%CI 1.05-1.50,P=0.042)。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,重症患者入院前使用糖皮质激素与入ICU后30天死亡率升高相关,该关联在合并糖尿病及服用>5 mg/日泼尼松龙和甲泼尼龙者中更常见。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: This study aimed to investigate the association between preadmission glucocorticoid (GC) therapy and 30-day mortality in critically ill patients following admission to an intensive care unit (ICU). We aimed to determine whether this association differed according to daily GC dosage and type. We conducted a retrospective cohort study of adult patients admitted to a single tertiary academic hospital ICU from January 2012 to December 2017. We classified the patients regularly undergoing oral GC therapy as preadmission GC users, and those with no history of GC use were classified as non-GC users.

RESULTS: The study included 24,929 patients, of whom 816 (3.3%) were preadmission GC users. Thirty-day mortality in preadmission GC users (173 of 816 patients) was 21.2% compared to 8.8% (2113 of 24,113 patients) in non-GC users. Multivariate Cox regression analysis showed that preadmission GC users had a 1.62-fold increase in 30-day mortality compared to non-GC users [hazard ratio (HR) 1.62, 95% confidence interval (CI) 1.29-2.03, P < 0.001]. When comparing preadmission GC users with diabetes mellitus to non-GC users, a 2.29-fold increase in 30-day mortality was noted (HR 2.29, 95% CI 1.08-4.86, P = 0.031). In the sensitivity analysis, compared to non-GC users, daily dosages of ≤ 5 and > 5 mg of prednisolone in preadmission GC users showed 1.45-fold (HR 1.45, 95% CI 1.03-2.03, P = 0.033) and 1.67-fold (HR 1.67, 95% CI 1.25-2.24, P = 0.001) increases, respectively, in 30-day mortality after ICU admission. Moreover, prednisolone, methylprednisolone, and dexamethasone users in the preadmission GC users group showed 1.56-fold (HR 1.56, 95% CI 1.21-2.01, P = 0.001), 1.90-fold (HR 1.90, 95% CI 1.12-3.25, P = 0.018), and 1.30-fold (HR 1.30, 95% CI 1.05-1.50, P = 0.042) increases, respectively, in 30-day mortality compared to non-GC users.

CONCLUSION: Preadmission GC use among critically ill patients was associated with an increased 30-day mortality after ICU admission compared to non-GC use. This association was more prevalent in preadmission GC users with diabetes mellitus and in preadmission GC users who took > 5 mg/day of prednisolone and methylprednisolone.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Oh TK, Song IA, Lee JH, et al. Effect of preadmission glucocorticoid therapy on 30-day mortality in critically ill patients: a retrospective study of a mixed ICU population in a tertiary hospital. Ann Intensive Care. 2019. PMID: 30659379. doi:10.1186/s13613-019-0489-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。